Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies against the acetylcholine receptor or against a receptor-associated protein, muscle-specific tyrosine kinase (MuSK-Ab).
The autoimmune attack at the muscle endplate leads to failure of neuromuscular transmission and eventually muscle weakness.
In the active phase of the disease, symptoms typically fluctuates and then become severe; myasthenic crisis occur in this phase.
In the stable/inactive phase, symptoms are stable but still persist; it usually worsen attributable to infection, fatigue, tapering of medications or other identifiable factors.
In the burnt-out phase, remission may occur wherein patients are on immunotherapy and symptom-free, or may even be off medications.
In 15-20 years, if the symptoms left untreated, patient's weakness becomes fixed wherein the most severely affected muscles become atrophic.
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 07 Apr 2020

A Spanish prospective multicentre study has identified a wider spectrum of paediatric demyelinating and encephalitic syndromes associated with myelin oligodendrocyte glycoprotein (MOG) antibodies than previously reported.

11 May 2020
Antireflux surgery results in improved quality of life (QOL) and reduced oesophageal acid exposure in neurologically normal (NN) and impaired (NI) children in the short and medium term, according to the results of a systematic review.
Elvira Manzano, 01 Aug 2019
Mums, but not dads, with migraine are more likely to have colicky babies, a large cross-sectional study finds.